<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Hubertus von Baumbach - Le Fonti New Pharma Italy</title>
	<atom:link href="https://www.newpharmaitaly.it/tag/hubertus-von-baumbach/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.newpharmaitaly.it/tag/hubertus-von-baumbach/</link>
	<description>Il portale delle news in ambito farmaceutico</description>
	<lastBuildDate>Thu, 01 Aug 2019 09:52:50 +0000</lastBuildDate>
	<language>it-IT</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://www.newpharmaitaly.it/wp-content/uploads/2022/12/cropped-favicon-new-pharma-italy-32x32.jpg</url>
	<title>Hubertus von Baumbach - Le Fonti New Pharma Italy</title>
	<link>https://www.newpharmaitaly.it/tag/hubertus-von-baumbach/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Boehringer Ingelheim: importanti investimenti in Ricerca e Sviluppo</title>
		<link>https://www.newpharmaitaly.it/boehringer-ingelheim-importanti-investimenti-in-ricerca-e-sviluppo/</link>
		
		<dc:creator><![CDATA[Elvis Kondi]]></dc:creator>
		<pubDate>Thu, 01 Aug 2019 09:52:50 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Boehringer Ingelheim]]></category>
		<category><![CDATA[digital health]]></category>
		<category><![CDATA[Hubertus von Baumbach]]></category>
		<category><![CDATA[R&D]]></category>
		<guid isPermaLink="false">https://www.newpharmaitaly.it/?p=3783</guid>

					<description><![CDATA[<p>Boehringer Ingelheim: Incremento del 4,6% del fatturato, spinto dalla Divisione Human Pharma. Confermata la previsione del Gruppo per il 2019. Nel primo semestre del 2019, l’azienda farmaceutica Boehringer Ingelheim, operante nel settore della ricerca, ha compiuto ulteriori progressi nel settore dell’R&#38;D. L’azienda si concentra principalmente sullo sviluppo di farmaci, nuovi approcci e nuove terapie per [&#8230;]</p>
<p>L'articolo <a href="https://www.newpharmaitaly.it/boehringer-ingelheim-importanti-investimenti-in-ricerca-e-sviluppo/">Boehringer Ingelheim: importanti investimenti in Ricerca e Sviluppo</a> proviene da <a href="https://www.newpharmaitaly.it">Le Fonti New Pharma Italy</a>.</p>
]]></description>
		
		
		
			</item>
	</channel>
</rss>
